BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:S150-S156. [PMID: 14615714 DOI: 10.1067/s0022-3476(03)00513-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005;18:541-55. [PMID: 16020689 DOI: 10.1128/CMR.18.3.541-555.2005] [Cited by in Crossref: 209] [Cited by in F6Publishing: 113] [Article Influence: 12.3] [Reference Citation Analysis]
2 Mauskopf J, Margulis AV, Samuel M, Lohr KN. Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review. Pediatr Infect Dis J 2016;35:e229-38. [PMID: 27093166 DOI: 10.1097/INF.0000000000001163] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
3 Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. [PMID: 21499597 DOI: 10.1155/2011/493056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
4 Qu XW, Duan ZJ, Qi ZY, Xie ZP, Gao HC, Liu WP, Huang CP, Peng FW, Zheng LS, Hou YD. Human bocavirus infection, People's Republic of China. Emerg Infect Dis 2007;13:165-8. [PMID: 17370538 DOI: 10.3201/eid1301.060842] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
5 Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis 2017;17:687. [PMID: 29041909 DOI: 10.1186/s12879-017-2803-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
6 Santibanez P, Gooch K, Vo P, Lorimer M, Sandino Y. Acute care utilization due to hospitalizations for pediatric lower respiratory tract infections in British Columbia, Canada. BMC Health Serv Res 2012;12:451. [PMID: 23217103 DOI: 10.1186/1472-6963-12-451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Lanari M, Anderson EJ, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray BS, Fullarton JR, Grubb E, Blanken M. Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies. Epidemiol Infect 2020;148:e170. [PMID: 32799945 DOI: 10.1017/S0950268820001661] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Townsi N, Laing IA, Hall GL, Simpson SJ. The impact of respiratory viruses on lung health after preterm birth. Eur Clin Respir J 2018;5:1487214. [PMID: 30128088 DOI: 10.1080/20018525.2018.1487214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
9 Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78. [PMID: 19063742 DOI: 10.1186/1465-9921-9-78] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
10 Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr 2012;171:1055-61. [PMID: 22302458 DOI: 10.1007/s00431-012-1673-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
11 Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol 2013;2013:359683. [PMID: 23840240 DOI: 10.1155/2013/359683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim D, Saleem M, Paes B, Mitchell I, Lanctôt KL. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017. Clin Infect Dis 2019;69:980-6. [PMID: 30517603 DOI: 10.1093/cid/ciy1010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 2012;31:2703-11. [PMID: 22546928 DOI: 10.1007/s10096-012-1617-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
14 Escobar GJ, Masaquel AS, Li SX, Walsh EM, Kipnis P. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr 2013;13:97. [PMID: 23782528 DOI: 10.1186/1471-2431-13-97] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
15 Anderson KS, Mullally VM, Fredrick LM, Campbell AL. Compliance with RSV prophylaxis: Global physicians' perspectives. Patient Prefer Adherence 2009;3:195-203. [PMID: 19936162 DOI: 10.2147/ppa.s5696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics 2010;126:115-28. [PMID: 20530073 DOI: 10.1542/peds.2009-1381] [Cited by in Crossref: 148] [Cited by in F6Publishing: 124] [Article Influence: 12.3] [Reference Citation Analysis]
17 Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71. [PMID: 17192118 DOI: 10.2165/00019053-200725010-00006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
18 Chang SG, Park MS, Yu JE. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. J Korean Med Sci 2010;25:251-6. [PMID: 20119579 DOI: 10.3346/jkms.2010.25.2.251] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
19 Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanctôt KL; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One 2015;10:e0134711. [PMID: 26237402 DOI: 10.1371/journal.pone.0134711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
20 Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, Greenough A. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax 2005;60:1039-44. [PMID: 16227330 DOI: 10.1136/thx.2004.037853] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
21 Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:F286-9. [PMID: 16036888 DOI: 10.1136/adc.2004.058081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
22 Bracht M, Basevitz D, Cranis M, Paulley R. Impact of respiratory syncytial virus: the nurse's perspective. Drugs R D 2011;11:215-26. [PMID: 21902285 DOI: 10.2165/11593140-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
23 Jang JE, Lee JB, Kim KH, Park SM, Shim BS, Cheon IS, Song MK, Chang J. Evaluation of protective efficacy of respiratory syncytial virus vaccine against A and B subgroup human isolates in Korea. PLoS One 2011;6:e23797. [PMID: 21915262 DOI: 10.1371/journal.pone.0023797] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
24 Resch B. Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr 2012; 1(3): 8-12 [PMID: 25254161 DOI: 10.5409/wjcp.v1.i3.8] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
25 Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infect Dis Ther 2016;5:417-52. [PMID: 27628014 DOI: 10.1007/s40121-016-0130-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
26 Drysdale SB, Prendergast M, Alcazar M, Wilson T, Smith M, Zuckerman M, Broughton S, Rafferty GF, Johnston SL, Hodemaekers HM, Janssen R, Bont L, Greenough A. Genetic predisposition of RSV infection-related respiratory morbidity in preterm infants. Eur J Pediatr 2014;173:905-12. [PMID: 24487983 DOI: 10.1007/s00431-014-2263-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
27 Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15. [PMID: 19967425 DOI: 10.1007/s10198-009-0206-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
28 Qu XW, Duan ZJ, Qi ZY, Xie ZP, Gao HC, Liu WP, Huang CP, Peng FW, Zheng LS, Hou YD. Human bocavirus infection, People's Republic of China. Emerg Infect Dis 2007;13:165-8. [PMID: 17370538 DOI: 10.3201/eid1301.060842] [Cited by in Crossref: 42] [Cited by in F6Publishing: 57] [Article Influence: 2.8] [Reference Citation Analysis]
29 Fleming PF, Richards S, Waterman K, Davis PG, Kamlin CO, Stewart M, Sokol J. Medical retrieval and needs of infants with bronchiolitis: an analysis by gestational age. J Paediatr Child Health 2013;49:E227-31. [PMID: 23227930 DOI: 10.1111/jpc.12025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J 2011;5:135-43. [PMID: 22262986 DOI: 10.2174/1874285801105010135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
31 Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. Int J Pediatr 2014;2014:571609. [PMID: 25548575 DOI: 10.1155/2014/571609] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
32 Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Rovers MM, Bont L; Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr 2018;177:133-44. [PMID: 29168012 DOI: 10.1007/s00431-017-3046-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
33 Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009;35:4. [PMID: 19490659 DOI: 10.1186/1824-7288-35-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
34 Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis 2008;27:891-9. [PMID: 18629558 DOI: 10.1007/s10096-008-0520-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]